Virax Biolabs Group Limited (VRAX) has partnered with Europa Biosite to distribute its ImmuneSelect research portfolio in the UK and Ireland, aiming to broaden its market presence and provide researchers and pharmaceutical companies with access to advanced immune profiling solutions. The deal marks a significant step for Virax Biolabs, following the launch of ImmuneSelect earlier this year and its commitment to addressing post-viral syndromes like Long COVID.